Immunic presents phase 2 trial data at multiple sclerosis meeting

May 28, 2026 6:30 AM

Immunic Inc. (NASDAQ: IMUX) presented additional data from its phase 2 CALLIPER trial of vidofludimus calcium for progressive multiple sclerosis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found